Systemic corticosteroids are the established primary treatment for the management of JDM. As yet, there is no consensus regarding the dose regimen and the therapeutic modalities. It is recommended to initiate the treatment with 1 milligram per kilogram of daily equivalent prednisone. Intravenous (IV) treatment is preferable in the case of gastrointestinal (GI) involvement. This late is known to be associated with vasculitis causing malabsorption. Long-term steroid treatment is usually required to achieve complete remission. It should be gradually decreased. Adjunctive hygienic-dietary measures, as well as daily supplementation with calcium and vitamin D,  must be systematic. However, these children are at high risk of osteoporosis.

In cases of therapeutic failure or significant side effects under steroid therapy, the use of subcutaneous methotrexate should be considered. Combining corticosteroids and methotrexate is a good alternative to control disease activity without significant adverse reactions.

For those who have dysphagia, occupational and speech therapy is necessary to educate the patient/family regarding food consistency and proper positioning of the chin, head, and tongue.